M Fogli
About
In The Last Decade
M Fogli
17 papers receiving 329 citations
Peers
Comparison fields: 5 of 46
- Hematology 245
- Immunology 124
- Oncology 112
- Molecular Biology 87
- Genetics 44
Countries citing papers authored by M Fogli
This map shows the geographic impact of M Fogli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Fogli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Fogli more than expected).
Fields of papers citing papers by M Fogli
This network shows the impact of papers produced by M Fogli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Fogli. The network helps show where M Fogli may publish in the future.
Co-authorship network of co-authors of M Fogli
This figure shows the co-authorship network connecting the top 25 collaborators of M Fogli. A scholar is included among the top collaborators of M Fogli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Fogli. M Fogli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | Dendritic cell differentiation from hematopoietic CD34+ progenitor cells. | 10 |
| 3 | 2 | |
| 4 | 3 | |
| 5 | Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies. | 20 |
| 6 | 27 | |
| 7 | 150 | |
| 8 | Persistence of non clonal hematopoietic progenitor cells in blastic phase chronic myelogenous leukemia (CML). Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of Bone Marrow Transplantation (EBMT). | 4 |
| 9 | Interleukin-11 (IL-11) and IL-9 counteract the inhibitory activity of transforming growth factor beta 3 (TGF-beta 3) on human primitive hematopoietic progenitor cells. | 7 |
| 10 | Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. | 15 |
| 11 | Stem cell factor (c-kit ligand) enhances the interleukin-9-dependent proliferation of human CD34+ and CD34+CD33-DR- cells. | 19 |
| 12 | 10 | |
| 13 | 12 | |
| 14 | Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD34+CD33-DR- cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor. | 51 |
| 15 | Effect of in vivo treatment with rh GM-CSF on in vitro growth of haematopoietic progenitors in patients with myelodysplastic syndromes. | 2 |
| 16 | 3 | |
| 17 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.